{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:31Z","timestamp":1793726071824,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03048-0","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:29:31Z","timestamp":1739903371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hansen Solubility Parameters, Computational, and Thermodynamic Models for Tofacitinib Citrate Solubility in Neat Mono Solvents, and GastroPlus Based Predicted In Vivo Performance of Subcutaneous Solution in Humans"],"prefix":"10.1208","volume":"26","author":[{"given":"Iman","family":"Ehsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudassar","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Faruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani Kumar","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7382-7052","authenticated-orcid":false,"given":"Tasneem","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"10","key":"3048_CR1","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","volume":"5","author":"GBD 2021 Rheumatoid Arthritis Collaborators","year":"2023","unstructured":"GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594\u2013610.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"3048_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00403-024-03314-4","volume":"316","author":"R Sun","year":"2024","unstructured":"Sun R, Fan H, Liu J, Gao G, Liu C, Zhang D, Ma W. The treatment of Tofacitinib for rosacea through the inhibition of the JAK\/STAT signaling pathway. Arch Dermatol Res. 2024;316(8):566. https:\/\/doi.org\/10.1007\/s00403-024-03314-4.","journal-title":"Arch Dermatol Res"},{"key":"3048_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1208\/s12249-019-1377-0","volume":"20","author":"US Younis","year":"2019","unstructured":"Younis US, Vallorz E, Addison KJ, Ledford JG, Myrdal PB. Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma. AAPS PharmSciTech. 2019;20:167. https:\/\/doi.org\/10.1208\/s12249-019-1377-0.","journal-title":"AAPS PharmSciTech"},{"key":"3048_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","volume":"22","author":"Q Liu","year":"2024","unstructured":"Liu Q, Liu M, Zou Z, Lin J, Zhang N, Zhao L, Zhou J, Zhou H, Zhou X, Jiao X, Yu Y, Liu T. Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study. J Transl Med. 2024;22:803. https:\/\/doi.org\/10.1186\/s12967-024-05617-6.","journal-title":"J Transl Med"},{"key":"3048_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12876-024-03336-2","volume":"24","author":"H Yoon","year":"2024","unstructured":"Yoon H, Ye BD, Kang S-B, Lee K-M, Choi CH, Jo J-Y, Woo J, Cheon JH. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study. BMC Gastroenterol. 2024;24:273. https:\/\/doi.org\/10.1186\/s12876-024-03336-2.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3048_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12348-023-00359-w","volume":"13","author":"A Manoharan","year":"2023","unstructured":"Manoharan A, Atmakur H, Dutta Majumder P, Biswas J. Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib. J Ophthal Inflamm Infect. 2023;13(1):45. https:\/\/doi.org\/10.1186\/s12348-023-00359-w.","journal-title":"J Ophthal Inflamm Infect"},{"issue":"8","key":"3048_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/03639045.2022.2119572","volume":"48","author":"S Nishal","year":"2022","unstructured":"Nishal S, Jhawat V, Phaugat P, Dutt R. In vitro characterization of tofacitinib loaded novel nanoemulgel for topical delivery for the management of rheumatic arthritis. Drug Dev Ind Pharm. 2022;48(8):374\u201383.","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"3048_CR8","first-page":"131","volume":"75","author":"Q Shen","year":"2020","unstructured":"Shen Q, Shu H, Xu X, Shu G, Du Y, Ying Y. Tofacitinib citrate-based liposomes for effective treatment of rheumatoid arthritis. Pharmazie. 2020;75(4):131\u20135.","journal-title":"Pharmazie"},{"key":"3048_CR9","doi-asserted-by":"publisher","first-page":"104145","DOI":"10.1016\/j.jddst.2022.104145","volume":"80","author":"S Atmakuri","year":"2023","unstructured":"Atmakuri S, Nene S, Jain H, Joga R, Devabattula G, Godugu C, Srivastava S. Topical delivery of tofacitinib citrate loaded novel nanoemulgel for the management of 2,4-Dichlorodinitrobenzene induced atopic dermatitis in mice model. J Drug Deliv Sci Technol. 2023;80:104145.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3048_CR10","doi-asserted-by":"publisher","first-page":"104789","DOI":"10.1016\/j.jddst.2023.104789","volume":"87","author":"H Roy","year":"2023","unstructured":"Roy H, Panda SP, Panda SK, Tripathi AK, Srivastava SK, Nayak BS, Singh PK, Singh GD. N-trimethyl chitosan and tripalmitin loaded solid lipid nanoparticles of tofacitinib citrate: Characterization and in-vivo anti-inflammatory assessment. J Drug Deliv Sci Technol. 2023;87:104789.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3048_CR11","doi-asserted-by":"publisher","first-page":"122387","DOI":"10.1016\/j.ijpharm.2022.122387","volume":"629","author":"H Hesham","year":"2022","unstructured":"Hesham H, Rady M, Hathout RM, Abdel-Halim M, Mansour S. The skin delivery of tofacitinib citrate using transethosomes and hybridized ethosomes\/nanostructured lipid carriers for vitiligo therapy: Dermatopharmacokinetics and in vivo assays. Int J Pharm. 2022;629:122387. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122387.","journal-title":"Int J Pharm"},{"issue":"4","key":"3048_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2174\/0126673878264814231106094853","volume":"17","author":"M Kuchukuntla","year":"2023","unstructured":"Kuchukuntla M, Palanivel V, Madhubabu A. Tofacitinib Citrate-loaded Nanoparticle Gel for the Treatment of Alopecia Areata: Response Surface Design, Formulation and In vitro-in Vivo Characterization. Recent Adv Drug Deliv Formulation. 2023;17(4):314\u201331.","journal-title":"Recent Adv Drug Deliv Formulation"},{"issue":"12","key":"3048_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/pharmaceutics12121131","volume":"12","author":"R Christmann","year":"2020","unstructured":"Christmann R, Ho DK, Wilzopolski J, Lee S, Koch M, Loretz B, Vogt T, B\u00e4umer W, Schaefer UF, Lehr CM. Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases. Pharmaceutics. 2020;12(12):1131. https:\/\/doi.org\/10.3390\/pharmaceutics12121131.","journal-title":"Pharmaceutics"},{"key":"3048_CR14","doi-asserted-by":"publisher","first-page":"8427","DOI":"10.3390\/ijms24098427","volume":"24","author":"Y Guan","year":"2023","unstructured":"Guan Y, Yan A, Qiang W, Ruan R, Yang C, Ma K, Sun H, Liu M, Zhu H. Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata. Int J Mol Sci. 2023;24:8427. https:\/\/doi.org\/10.3390\/ijms24098427.","journal-title":"Int J Mol Sci"},{"key":"3048_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1208\/s12249-024-02800-2","volume":"25","author":"A Malik","year":"2024","unstructured":"Malik A, Khan T, Siddique MUM, Faruk A, Sood AK, Bhat ZR. HSPiP, Computational, and Thermodynamic Model-Based Optimized Solvents for Subcutaneous Delivery of Tolterodine Tartrate and GastroPlus-Based In Vivo Prediction in Humans: Part I. AAPS PharmSciTech. 2024;25:93. https:\/\/doi.org\/10.1208\/s12249-024-02800-2.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3048_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1021\/acsomega.1c05788","volume":"7","author":"A Hussain","year":"2022","unstructured":"Hussain A, Altamimi MA, Afzal O, Altamimi ASA, Ali A, Ali A, Martinez F, Siddique MUM Jr, Acree WE, Jouyban A. Preferential Solvation Study of the Synthesized Aldose Reductase Inhibitor (SE415) in the {PEG 400 (1) + Water (2)} Cosolvent Mixture and GastroPlus-Based Prediction. ACS Omega. 2022;7(1):1197\u2013210.","journal-title":"ACS Omega"},{"key":"3048_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s43094-021-00325-0","volume":"7","author":"S Gorantla","year":"2021","unstructured":"Gorantla S, Saha RN, Singhvi G. Design of experiment-driven stability-indicating RP-HPLC method for the determination of tofacitinib in nanoparticles and skin matrix. Futur J Pharm Sci. 2021;7:180. https:\/\/doi.org\/10.1186\/s43094-021-00325-0.","journal-title":"Futur J Pharm Sci"},{"key":"3048_CR18","doi-asserted-by":"crossref","unstructured":"Huggins ML. The solubility of nonelectrolytes. By Joel H. Hildebrand and Robert S. Scott. J Phys Chem. 1951;55(4):619\u201320.","DOI":"10.1021\/j150487a027"},{"key":"3048_CR19","doi-asserted-by":"crossref","unstructured":"Lan Y, Corradini MG, Liu X, May TE, Borondics F, Weiss RG, Rogers MA. Comparing and correlating solubility parameters governing the self-assembly of molecular gels using 1,3:2,4-Dibenzylidene Sorbitol as the Gelator. Langmuir. 2014;30(47):14128\u201342.","DOI":"10.1021\/la5008389"},{"key":"3048_CR20","doi-asserted-by":"publisher","unstructured":"Lu C, Jin Z, Li H. Determination of Hildebrand solubility parameter for pure hydrocarbons by incorporating temperature-dependent volume translation into peng-robinson equation of state. J Supercrit Fluids. 2020;104945. https:\/\/doi.org\/10.1016\/j.supflu.2020.104945.","DOI":"10.1016\/j.supflu.2020.104945"},{"key":"3048_CR21","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/molecules26113091","volume":"26","author":"M Ghazwani","year":"2021","unstructured":"Ghazwani M, Alam P, Alqarni MH, Yusufoglu HS, Shakeel F. Solubilization of Trans-Resveratrol in Some Mono-Solvents and Various Propylene Glycol + Water Mixtures. Molecules. 2021;26:3091. https:\/\/doi.org\/10.3390\/molecules26113091.","journal-title":"Molecules"},{"key":"3048_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.fluid.2010.09.027","volume":"299","author":"MA Ruidiaz","year":"2010","unstructured":"Ruidiaz MA, Delgado DR, Mart\u00ednez F, Marcus Y. Solubility and preferential solvation of indomethacin in 1,4-dioxane + water solvent mixtures. Fluid Phase Equilib. 2010;299:259\u201365.","journal-title":"Fluid Phase Equilib"},{"key":"3048_CR23","doi-asserted-by":"publisher","unstructured":"Afzal O, Alshammari HA, Altamimi MA, Hussain A, Almohaywi B, Altamimi ASA. Hansen solubility parameters and green nanocarrier based removal of trimethoprim from contaminated aqueous solution.\u00a0J Mol Liq. 2022; 361:119657. https:\/\/doi.org\/10.1016\/j.molliq.2022.119657.","DOI":"10.1016\/j.molliq.2022.119657"},{"key":"3048_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/jcht.1998.0424","volume":"31","author":"A Apelblat","year":"1999","unstructured":"Apelblat A, Manzurola E. Solubilities of o-acetylsalicylic, 4-aminosalicylic, 3,5-dinitrosalicylic and p-toluic acid and magnesium-DL-aspartate in water from T = 20 (278\u2013348) K. J Chem Thermodyn. 1999;31:85\u201391.","journal-title":"J Chem Thermodyn"},{"key":"3048_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1006\/jcht.2002.0975","volume":"34","author":"E Manzurola","year":"2002","unstructured":"Manzurola E, Apelblat A. Solubilities of L-glutamic acid, 3-nitrobenzoic acid, acetylsalicylic, p-toluic acid, calcium-L-lactate, calcium gluconate, magnesium-DL- aspartate, and magnesium-L-lactate in water. J Chem Thermodyn. 2002;34:1127\u201336.","journal-title":"J Chem Thermodyn"},{"key":"3048_CR26","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1021\/j100562a007","volume":"80","author":"RR Krug","year":"1976","unstructured":"Krug RR, Hunter WG, Grieger RS. Enthalpy-entropy compensation. 2. Separation 5 of the chemical from the statistic effect. J Phys Chem. 1976;80:2341\u201351.","journal-title":"J Phys Chem"},{"key":"3048_CR27","doi-asserted-by":"publisher","unstructured":"Hussain A, Altamimi MA, Alneef YS. HSPiP and QbD oriented optimized stearylamine-elastic liposomes for topical delivery of ketoconazole to treat deep seated fungal infections: In vitro and ex vivo evaluations. Int J Pharm X. 2024; 26(8):100279. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100279.","DOI":"10.1016\/j.ijpx.2024.100279"},{"issue":"1","key":"3048_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/acsomega.9b02800","volume":"5","author":"K Sanachai","year":"2020","unstructured":"Sanachai K, Mahalapbutr P, Choowongkomon K, Poo-Arporn RP, Wolschann P, Rungrotmongkol T. Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases. ACS Omega. 2020;5(1):369\u201377.","journal-title":"ACS Omega"},{"issue":"1","key":"3048_CR29","doi-asserted-by":"publisher","first-page":"11636","DOI":"10.1038\/s41598-020-68350-2","volume":"10","author":"M Roche-Molina","year":"2020","unstructured":"Roche-Molina M, Hardwick B, Sanchez-Ramos C, Sanz-Rosa D, Gewert D, Cruz FM, Gonzalez-Guerra A, Andres V, Palma JA, Ibanez B, Mckenzie G, Bernal JA. The pharmaceutical solvent N-methyl-2-pyrollidone (NMP) attenuates inflammation through Kr\u00fcppel-like factor 2 activation to reduce atherogenesis. Sci Rep. 2020;10(1):11636. https:\/\/doi.org\/10.1038\/s41598-020-68350-2.","journal-title":"Sci Rep"},{"issue":"2","key":"3048_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1208\/s12249-008-9050-z","volume":"9","author":"R Sanghvi","year":"2008","unstructured":"Sanghvi R, Narazaki SG, Machatha SH. Yalkowsky, Solubility improvement of drugs using N-methyl pyrrolidone. AAPS PharmSciTech. 2008;9(2):366\u201376.","journal-title":"AAPS PharmSciTech"},{"key":"3048_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijpharm.2011.01.030","volume":"407","author":"MA Mohammad","year":"2011","unstructured":"Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool 5 to predict cocrystal formation. Int J Pharm. 2011;407:63\u201371.","journal-title":"Int J Pharm"},{"key":"3048_CR32","doi-asserted-by":"publisher","first-page":"112211","DOI":"10.1016\/j.molliq.2019.112211","volume":"299","author":"A Alanazi","year":"2020","unstructured":"Alanazi A, Alshehri S, Altamimi M, Shakeel F. Solubility determination and three dimensional Hansen solubility parameters of gefitinib in different organic solvents: Experimental and computational approaches. J Mol Liq. 2020;299:112211. https:\/\/doi.org\/10.1016\/j.molliq.2019.112211.","journal-title":"J Mol Liq"},{"key":"3048_CR33","doi-asserted-by":"crossref","unstructured":"Nor MSM, Manan ZA, Mustaffa AA, Suan CL. An evaluation of thermodynamic models for the prediction of solubility of phytochemicals from orthosiphon staminues in ethanol. Comput Aided Chem Eng. 2015;37:2087\u201392.","DOI":"10.1016\/B978-0-444-63576-1.50042-X"},{"key":"3048_CR34","first-page":"1","volume":"20180311","author":"Z Sayyar","year":"2019","unstructured":"Sayyar Z, Jafarizadeh-Malmiri H. Temperature effects on thermodynamic parameters and solubility of curcumin O\/W nanodispersions using different thermodynamic models. Int J Food Eng. 2019;20180311:1\u201313.","journal-title":"Int J Food Eng"},{"key":"3048_CR35","first-page":"325","volume-title":"Pharmaceutical preformulation and formulation","author":"J Broadhead","year":"2009","unstructured":"Broadhead J, Gibson M. Parenteral dosage forms. In: Gibson M, editor. Pharmaceutical preformulation and formulation. New York: Informa healthcare; 2009. p. 325\u201347."},{"key":"3048_CR36","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris J-E. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019;36:2986\u201396.","journal-title":"Adv Ther"},{"issue":"2","key":"3048_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/bja\/66.2.189","volume":"66","author":"W Klement","year":"1991","unstructured":"Klement W, Arndt JO. Pain on i.v. injection of some anaesthetic agents is evoked by the unphysiological osmolality or pH of their formulations. Br J Anaesth. 1991;66(2):189\u201395.","journal-title":"Br J Anaesth"},{"issue":"3","key":"3048_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11095-022-03190-5","volume":"40","author":"AA Dandekar","year":"2023","unstructured":"Dandekar AA, Garimella HT, German CL, Banga AK. Microneedle Mediated Iontophoretic Delivery of Tofacitinib Citrate. Pharm Res. 2023;40(3):735\u201347.","journal-title":"Pharm Res"},{"key":"3048_CR39","doi-asserted-by":"crossref","unstructured":"Banga AK. Transdermal and intradermal delivery of therapeutic agents application of physical technologies. 1st Edition. CRC Press. Boca Raton: CRC Press; 2011;309:26\u201340.","DOI":"10.1201\/b10906"},{"key":"3048_CR40","doi-asserted-by":"crossref","unstructured":"Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. JAAD Case Rep. 2018;4(10):988\u20139.","DOI":"10.1016\/j.jdcr.2018.07.018"},{"key":"3048_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13256-023-03821-4","volume":"17","author":"M Mardani","year":"2023","unstructured":"Mardani M, Mohammadshahi J, Abolghasemi S, Teimourpour R. Drug-induced liver injury due to tofacitinib: a case report. J Med Case Reports. 2023;17:97. https:\/\/doi.org\/10.1186\/s13256-023-03821-4.","journal-title":"J Med Case Reports"},{"key":"3048_CR42","unstructured":"US FDA label. XELJANZ. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. Accessed on 30th March, 2024."},{"issue":"4","key":"3048_CR43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor. Hum Drug Metab Disposit. 2014;42(4):759\u201373.","journal-title":"Hum Drug Metab Disposit"},{"issue":"1","key":"3048_CR44","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.xphs.2018.11.008","volume":"108","author":"A Kambayashi","year":"2019","unstructured":"Kambayashi A, Dressman J. Predicting the changes in oral absorption of weak base drugs under elevated gastric pH using an in vitro \u2013 in silico \u2013 in vivo approach: case examples dipyridamole, prasugrel and nelfinavir. J Pharm Sci. 2019;108(1):584\u201391.","journal-title":"J Pharm Sci"},{"key":"3048_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1208\/s12249-021-02075-x","volume":"22","author":"A Hussain","year":"2021","unstructured":"Hussain A, Altamimi MA, Alshehri S, Imam SS, Alnemer UA, Haque MW. Experimental Solubility of Ketoconazole, Validation Models, and In vivo Prediction in Human Based on GastroPlus. AAPS PharmSciTech. 2021;22:194. https:\/\/doi.org\/10.1208\/s12249-021-02075-x.","journal-title":"AAPS PharmSciTech"},{"key":"3048_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1208\/s12249-021-01987-y","volume":"22","author":"WA Mahdi","year":"2021","unstructured":"Mahdi WA, Hussain A, Altamimi MA, Alshehri S, Bukhari S, Ahsan MN. Experimental Solubility, Thermodynamic\/Computational Validations, and GastroPlus-Based In Silico Prediction for Subcutaneous Delivery of Rifampicin. AAPS PharmSciTech. 2021;22:116. https:\/\/doi.org\/10.1208\/s12249-021-01987-y.","journal-title":"AAPS PharmSciTech"},{"key":"3048_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/s12249-023-02577-w)","volume":"24","author":"SS Kesharwani","year":"2023","unstructured":"Kesharwani SS, Ibrahim F. A Combined In-Vitro and GastroPlus\u00ae Modeling to Study the Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in a Fasted State. AAPS PharmSciTech. 2023;24:121. https:\/\/doi.org\/10.1208\/s12249-023-02577-w).","journal-title":"AAPS PharmSciTech"},{"key":"3048_CR48","unstructured":"FDA. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 2019. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and. Accessed 5 Dec 2024."},{"key":"3048_CR49","doi-asserted-by":"publisher","first-page":"119558","DOI":"10.1016\/j.ijpharm.2020.119558","volume":"585","author":"H Kathuria","year":"2020","unstructured":"Kathuria H, Nguyen DTP, Handral HK, Cai J, Cao T, Kang L. Proposome for transdermal delivery of tofacitinib. Int J Pharm. 2020;585:119558.","journal-title":"Int J Pharm"},{"issue":"1","key":"3048_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","volume":"169","author":"WC Ports","year":"2013","unstructured":"Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137\u201345.","journal-title":"Br J Dermatol"},{"key":"3048_CR51","doi-asserted-by":"publisher","first-page":"120152","DOI":"10.1016\/j.ijpharm.2020.120152","volume":"593","author":"\u00c1 C\u00e1rcamo-Mart\u00ednez","year":"2021","unstructured":"C\u00e1rcamo-Mart\u00ednez \u00c1, Mallon B, Anjani QK, Dom\u00ednguez-Robles J, Utomo E, Vora LK, Tekko IA, Larraneta E, Donnelly RF. Enhancing intradermal delivery of tofacitinib citrate: Comparison between powder-loaded hollow microneedle arrays and dissolving microneedle arrays. Int J Pharm. 2021;593:120152. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120152.","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03048-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03048-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03048-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T17:17:59Z","timestamp":1748539079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03048-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3048"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03048-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No animal involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Concerns"}}],"article-number":"64"}}